Praxis Precision Medicines (NASDAQ:PRAX) Stock Acquired by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Praxis Precision Medicines stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Praxis Precision Medicines Stock Performance

Shares of PRAX opened at $243.34 on Wednesday. Praxis Precision Medicines, Inc. has a fifty-two week low of $50.56 and a fifty-two week high of $392.70. The company’s fifty day moving average is $328.11 and its 200 day moving average is $319.59. The stock has a market capitalization of $6.79 billion, a PE ratio of -18.82 and a beta of 2.79.

Praxis Precision Medicines (NASDAQ:PRAX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($2.87) EPS for the quarter, topping analysts’ consensus estimates of ($3.67) by $0.80. As a group, research analysts forecast that Praxis Precision Medicines, Inc. will post -13.90 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. GAMMA Investing LLC increased its holdings in Praxis Precision Medicines by 10.3% during the second quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock valued at $111,000 after buying an additional 31 shares during the period. KBC Group NV raised its stake in Praxis Precision Medicines by 5.8% in the first quarter. KBC Group NV now owns 715 shares of the company’s stock worth $230,000 after buying an additional 39 shares in the last quarter. Carl P. Sherr & Co. LLC lifted its holdings in Praxis Precision Medicines by 8.4% during the first quarter. Carl P. Sherr & Co. LLC now owns 972 shares of the company’s stock worth $313,000 after buying an additional 75 shares during the period. Integrated Wealth Concepts LLC bought a new stake in Praxis Precision Medicines during the 2nd quarter valued at $38,000. Finally, Parallel Advisors LLC boosted its position in Praxis Precision Medicines by 3,000.0% during the 1st quarter. Parallel Advisors LLC now owns 124 shares of the company’s stock valued at $40,000 after acquiring an additional 120 shares in the last quarter. Hedge funds and other institutional investors own 67.84% of the company’s stock.

Wall Street Analyst Weigh In

PRAX has been the topic of a number of recent research reports. Piper Sandler restated an “overweight” rating on shares of Praxis Precision Medicines in a research report on Monday, July 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Praxis Precision Medicines in a research report on Monday, August 24th. Needham & Company LLC reissued a “buy” rating and set a $582.00 target price on shares of Praxis Precision Medicines in a research report on Thursday, September 24th. Wall Street Zen upgraded Praxis Precision Medicines from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, HC Wainwright restated a “buy” rating and issued a $1,201.00 price target on shares of Praxis Precision Medicines in a research report on Tuesday, October 6th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $613.26.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company uses insights from human genetics, neuroscience and its Cerebrum™ platform to identify and advance medicines for conditions in which existing treatment options may be limited.

Praxis’ pipeline has included investigational treatments for epilepsies and other neurological disorders, including developmental and epileptic encephalopathies, essential tremor and movement-related conditions.